Intestinal permeability and its relevance for absorption and elimination
暂无分享,去创建一个
[1] T. Lundstedt,et al. Presentation of a structurally diverse and commercially available drug data set for correlation and benchmarking studies. , 2006, Journal of medicinal chemistry.
[2] H. Lennernäs,et al. Enantiometric separation of verapamil and norverapamil using Chiral-AGP as the stationary phase. , 1999, Journal of pharmaceutical and biomedical analysis.
[3] H. Lennernäs,et al. The lack of effect of induced net fluid absorption on the in vivo permeability of terbutaline in the human jejunum. , 1995, Journal of drug targeting.
[4] R. Modigliani,et al. The method of intraluminal perfusion of the human small intestine. 3. Absorption studies in disease. , 1973, Digestion.
[5] T. Gramatté,et al. Paracetamol absorption from different sites in the human small intestine. , 1994, British journal of clinical pharmacology.
[6] J. Gorski,et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin , 1998, Clinical pharmacology and therapeutics.
[7] R. Oertel,et al. Intestinal secretion of intravenous talinolol is inhibited by luminal R‐verapamil , 1999, Clinical pharmacology and therapeutics.
[8] G. Williamson,et al. Absorption/metabolism of sulforaphane and quercetin, and regulation of phase II enzymes, in human jejunum in vivo. , 2003, Drug metabolism and disposition: the biological fate of chemicals.
[9] J. Schellens,et al. Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] David J Brayden,et al. Keynote review: intestinal Peyer's patch M cells and oral vaccine targeting. , 2005, Drug discovery today.
[11] K. Soergel. Showdown at the tight junction. , 1993, Gastroenterology.
[12] H. Lennernäs,et al. Regional Jejunal Perfusion, a New in Vivo Approach to Study Oral Drug Absorption in Man , 1995, Pharmaceutical Research.
[13] Wolfgang Sadee,et al. 5′-Amino Acid Esters of Antiviral Nucleosides, Acyclovir, and AZT Are Absorbed by the Intestinal PEPT1 Peptide Transporter , 1998, Pharmaceutical Research.
[14] S. Nylander,et al. Jejunal Permeability: A Comparison Between the Ussing Chamber Technique and the Single-Pass Perfusion in Humans , 1997, Pharmaceutical Research.
[15] M. Rongier,et al. Intestinal Absorption of Amiodarone in Man , 1990, Journal of clinical pharmacology.
[16] A. Rane,et al. Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract. , 2005, British journal of clinical pharmacology.
[17] H. Lennernäs,et al. St John's Wort Decreases the Bioavailability of R‐ and S‐verapamil Through Induction of the First‐pass Metabolism , 2004, Clinical pharmacology and therapeutics.
[18] Julia Qiu,et al. Interactions of Human P-glycoprotein with Simvastatin, Simvastatin Acid, and Atorvastatin , 2004, Pharmaceutical Research.
[19] O. Corrigan. The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. , 1997, Advances in experimental medicine and biology.
[20] H. Lennernäs,et al. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. , 2003, British journal of clinical pharmacology.
[21] H. Lennernäs,et al. Intestinal drug absorption during induced net water absorption in man; a mechanistic study using antipyrine, atenolol and enalaprilat. , 1994, British journal of clinical pharmacology.
[22] Yuichi Sugiyama,et al. Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect , 2007, Drug Metabolism and Disposition.
[23] D. Thakker,et al. Differential Substrate and Inhibitory Activities of Ranitidine and Famotidine toward Human Organic Cation Transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3) , 2005, Journal of Pharmacology and Experimental Therapeutics.
[24] H Lennernäs,et al. Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.
[25] J. H. I. Huis in't Veld,et al. Overview of gut flora and probiotics. , 1998, International journal of food microbiology.
[26] G. M. Pollack,et al. Intestinal Absorptive Transport of the Hydrophilic Cation Ranitidine: A Kinetic Modeling Approach to Elucidate the Role of Uptake and Efflux Transporters and Paracellular vs. Transcellular Transport in Caco-2 Cells , 2006, Pharmaceutical Research.
[27] W. L. Chiou,et al. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. , 2001, International journal of clinical pharmacology and therapeutics.
[28] D. Winne. The permeability coefficient of the wall of a villous membrane , 1978, Journal of mathematical biology.
[29] G. Amidon,et al. CHO/hPEPT1 cells overexpressing the human peptide transporter (hPEPT1) as an alternative in vitro model for peptidomimetic drugs. , 1999, Journal of pharmaceutical sciences.
[30] R. Modigliani,et al. The method of intraluminal perfusion of the human small intestine. II. Absorption studies in health. , 1973, Digestion.
[31] W. Heizer,et al. In Vitro–In Vivo Correlation of Hepatobiliary Drug Clearance in Humans , 2007, Clinical pharmacology and therapeutics.
[32] D. Winne. Dependence of intestinal absorption in vivo on the unstirred layer , 1978, Naunyn-Schmiedeberg's Archives of Pharmacology.
[33] W. Couet,et al. Enhanced Oral Paclitaxel Bioavailability After Administration of Paclitaxel-Loaded Lipid Nanocapsules , 2006, Pharmaceutical Research.
[34] G. Amidon,et al. A Residence‐Time Distribution Analysis of the Hydrodynamics within the Intestine in Man during a Regional Single‐pass Perfusion with Loc‐I‐Gut: In‐vivo Permeability Estimation , 1997, The Journal of pharmacy and pharmacology.
[35] M Rowland,et al. Differentiation of absorption and first‐pass gut and hepatic metabolism in humans: Studies with cyclosporine , 1995, Clinical pharmacology and therapeutics.
[36] Ken Grime,et al. Use of Hepatocytes to Assess the Contribution of Hepatic Uptake to Clearance in Vivo , 2007, Drug Metabolism and Disposition.
[37] M. Rowland,et al. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liverin situ preparation , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[38] Hans Lennernäs,et al. Comparison Between Permeability Coefficients in Rat and Human Jejunum , 1996, Pharmaceutical Research.
[39] H. Lennernäs,et al. The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in‐vivo perfusion in humans , 2002, The Journal of pharmacy and pharmacology.
[40] L. Benet,et al. The drug efflux-metabolism alliance: biochemical aspects. , 2001, Advanced drug delivery reviews.
[41] M. Hedeland,et al. Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers. , 2006, International journal of clinical pharmacology and therapeutics.
[42] M C Willingham,et al. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[43] I. Wilding,et al. Oral drug absorption studies: the best model for man is man! , 2001, Drug discovery today.
[44] A. Grahnén,et al. Nonlinearity of amoxicillin absorption kinetics in human , 2006, European Journal of Clinical Pharmacology.
[45] C. Higgins,et al. Multiple molecular mechanisms for multidrug resistance transporters , 2007, Nature.
[46] H. Lennernäs. Intestinal drug absorption and bioavailability: beyond involvement of single transport function , 2003, The Journal of pharmacy and pharmacology.
[47] J. Crison,et al. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.
[48] G. Amidon,et al. Oral Absorption of Peptides: Influence of pH and Inhibitors on the Intestinal Hydrolysis of Leu-Enkephalin and Analogues , 2004, Pharmaceutical Research.
[49] G. Amidon,et al. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[50] H. Lennernäs,et al. Repeated oral rifampicin decreases the jejunal permeability of R/S-verapamil in rats. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[51] Shiew-Mei Huang,et al. Optimising drug development: Strategies to assess drug metabolism/transporter interaction potential - Towards a consensus , 2001 .
[52] I. Wilding,et al. Systemic Availability of the Active Metabolite Hydroxy‐Fasudil After Administration of Fasudil to Different Sites of the Human Gastrointestinal Tract , 2007, Journal of clinical pharmacology.
[53] Hannelore Daniel,et al. Molecular and integrative physiology of intestinal peptide transport. , 2004, Annual review of physiology.
[54] Gordon L. Amidon,et al. Comparison of Human Duodenum and Caco-2 Gene Expression Profiles for 12,000 Gene Sequences Tags and Correlation with Permeability of 26 Drugs , 2002, Pharmaceutical Research.
[55] Ho-Chul Shin,et al. Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model , 2006, Pharmaceutical Research.
[56] G. Olaison,et al. Absorption Profiles for Polyethylene Glycols After Regional Jejunal Perfusion and Oral Load in Healthy Humans , 1997, Digestive Diseases and Sciences.
[57] G. Warhurst,et al. Region-Dependent Modulation of Intestinal Permeability by Drug Efflux Transporters: In Vitro Studies in mdr1a(−/−) Mouse Intestine , 2002, Journal of Pharmacology and Experimental Therapeutics.
[58] D. Meijer,et al. The stereoisomers quinine and quinidine exhibit a marked stereoselectivity in the inhibition of hepatobiliary transport of cardiac glycosides. , 1998, Journal of hepatology.
[59] H. Daniel,et al. The proton oligopeptide cotransporter family SLC15 in physiology and pharmacology , 2004, Pflügers Archiv.
[60] S. Frokjaer,et al. Delivery aspects of small peptides and substrates for peptide transporters. , 2005, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[61] H. Lennernäs,et al. Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. , 2007, International journal of pharmaceutics.
[62] K. Schenck-Gustafsson,et al. Digoxin‐verapamil interaction: Reduction of biliary but not renal digoxin clearance in humans , 1991, Clinical pharmacology and therapeutics.
[63] Hans Lennernäs,et al. Biliary secretion of rosuvastatin and bile acids in humans during the absorption phase. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[64] R. Kim,et al. Intestinal Drug Transporter Expression and the Impact of Grapefruit Juice in Humans , 2007, Clinical pharmacology and therapeutics.
[65] M. Rowland,et al. Resolution of P‐glycoprotein and non‐P‐glycoprotein effects on drug permeability using intestinal tissues from mdr1a (−/−) mice , 2002, British journal of pharmacology.
[66] H. Lennernäs,et al. Regional Rectal Perfusion: A New in Vivo Approach to Study Rectal Drug Absorption in Man , 2004, Pharmaceutical Research.
[67] B. Angelin,et al. Digoxin-interactions in man: Spironolactone reduces renal but not biliary digoxin clearance , 2004, European Journal of Clinical Pharmacology.
[68] Hans Lennernäs,et al. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension , 2005, The Journal of pharmacy and pharmacology.
[69] Hirst,et al. Development of a new engineering-based capsule for human drug absorption studies. , 2000, Pharmaceutical science & technology today.
[70] Morton B. Brown,et al. Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine , 1997, Clinical pharmacology and therapeutics.
[71] B. Angelin,et al. No effect of probenecid on the renal and biliary clearances of digoxin in man. , 1991, British journal of clinical pharmacology.
[72] L. Benet,et al. Tacrolimus oral bioavailability doubles with coadministration of ketoconazole , 1997, Clinical pharmacology and therapeutics.
[73] A. Hofmann,et al. Measurements of intestinal permeability using low molecular weight polyethylene glycols (PEG 400). I. Chemical analysis and biological properties of PEG 400. , 1977, Gastroenterology.
[74] H Lennernäs,et al. Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.
[75] Hans Lennernäs,et al. Does Fluid Flow Across the Intestinal Mucosa Affect Quantitative Oral Drug Absorption? Is It Time for a Reevaluation? , 1995, Pharmaceutical Research.
[76] A. Grahnén. Cimetidine bioavailability and variable renal clearance , 2004, European Journal of Clinical Pharmacology.
[77] Malcolm Rowland,et al. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance , 1977, Journal of Pharmacokinetics and Biopharmaceutics.
[78] T. Gramatté. Griseofulvin absorption from different sites in the human small intestine , 1994, Biopharmaceutics & drug disposition.
[79] B. Angelin,et al. Dose-dependent absorption of amoxicillin in patients with an ileostomy , 2006, European Journal of Clinical Pharmacology.
[80] Per Artursson,et al. Expression of Thirty-six Drug Transporter Genes in Human Intestine, Liver, Kidney, and Organotypic Cell Lines , 2007, Drug Metabolism and Disposition.
[81] G. Amidon,et al. Human Jejunal Permeability of Two Polar Drugs: Cimetidine and Ranitidine , 2001, Pharmaceutical Research.
[82] Leslie Z. Benet,et al. Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System , 2004, Pharmaceutical Research.
[83] G. M. Pollack,et al. Kinetic Considerations for the Quantitative Assessment of Efflux Activity and Inhibition: Implications for Understanding and Predicting the Effects of Efflux Inhibition , 2007, Pharmaceutical Research.
[84] N. Read,et al. Effect of gastrointestinal intubation on the passage of a solid meal through the stomach and small intestine in humans. , 1983, Gastroenterology.
[85] H. Lennernäs,et al. EUFEPS conference on drug transporters at Copenhagen: integrative approaches in ADME research. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[86] H. Lennernäs,et al. Gene and protein expression of P-glycoprotein, MRP1, MRP2, and CYP3A4 in the small and large human intestine. , 2007, Molecular pharmaceutics.
[87] W. H. Barr,et al. Differential absorption of amoxicillin from the human small and large intestine , 1994, Clinical pharmacology and therapeutics.
[88] I. Tamai,et al. Transporter-mediated intestinal absorption of fexofenadine in rats. , 2006, Drug metabolism and pharmacokinetics.
[89] S. Yalkowsky,et al. Mass transport phenomena and models: theoretical concepts. , 1974, Journal of pharmaceutical sciences.
[90] M Rowland,et al. Kinetic profiling of P-glycoprotein-mediated drug efflux in rat and human intestinal epithelia. , 2001, The Journal of pharmacology and experimental therapeutics.
[91] H vandeWaterbeemd,et al. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. , 1998 .
[92] G. Amidon,et al. Human Jejunal Permeability of Cyclosporin A: Influence of Surfactants on P-Glycoprotein Efflux in Caco-2 Cells , 2003, Pharmaceutical Research.
[93] M. Rowland,et al. Modulation of the permeability of H2 receptor antagonists cimetidine and ranitidine by P-glycoprotein in rat intestine and the human colonic cell line Caco-2. , 1999, The Journal of pharmacology and experimental therapeutics.
[94] H. Lennernäs,et al. Investigations of the In‐vitro Metabolism of Three Opioid Tetrapeptides by Pancreatic and Intestinal Enzymes , 2000, The Journal of pharmacy and pharmacology.
[95] Vinod P. Shah,et al. The Use of BDDCS in Classifying the Permeability of Marketed Drugs , 2008, Pharmaceutical Research.
[96] S. Weir,et al. Pharmacokinetics, pharmacodynamics, and tolerance of single‐ and multiple‐dose fexofenadine hydrochloride in healthy male volunteers , 1998, Clinical pharmacology and therapeutics.
[97] P. Artursson,et al. Efflux transporters in ulcerative colitis: Decreased expression of BCRP (ABCG2) and Pgp (ABCB1) , 2007, Inflammatory bowel diseases.
[98] J. Schellens,et al. Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut , 2002, Cancer Chemotherapy and Pharmacology.
[99] B. Angelin,et al. Interactions in the renal and biliary elimination of digoxin: Stereoselective difference between quinine and quinidine , 1990, Clinical pharmacology and therapeutics.
[100] U. Christians,et al. Mechanisms of Clinically Relevant Drug Interactions Associated with Tacrolimus , 2002, Clinical pharmacokinetics.
[101] H. Lennernäs,et al. FIRST-PASS EFFECTS OF VERAPAMIL ON THE INTESTINAL ABSORPTION AND LIVER DISPOSITION OF FEXOFENADINE IN THE PORCINE MODEL , 2006, Drug Metabolism and Disposition.
[102] G. Amidon,et al. Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. , 2002, Journal of pharmaceutical sciences.
[103] Paul B Watkins,et al. Differential Inhibition of Rat and Human Na+-Dependent Taurocholate Cotransporting Polypeptide (NTCP/SLC10A1)by Bosentan: A Mechanism for Species Differences in Hepatotoxicity , 2007, Journal of Pharmacology and Experimental Therapeutics.
[104] L J Lesko,et al. Drug Interaction Studies: Study Design, Data Analysis, and Implications for Dosing and Labeling , 2007, Clinical pharmacology and therapeutics.
[105] W. Kirch,et al. Induction of Intestinal P‐glycoprotein by St John's Wort Reduces the Oral Bioavailability of Talinolol , 2007, Clinical pharmacology and therapeutics.
[106] EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential - towards a consensus. European Federation of Pharmaceutical Sciences. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[107] H. Lennernäs,et al. Folate absorption from folate-fortified and processed foods using a human ileostomy model , 2006, British Journal of Nutrition.
[108] P. Sinko,et al. Intestinal drug transporters: in vivo function and clinical importance. , 2004, Current drug metabolism.
[109] S. Riley,et al. The influence of gastrointestinal transit on drug absorption in healthy volunteers. , 1992, British journal of clinical pharmacology.
[110] H Lennernäs,et al. Membrane transport of drugs in different regions of the intestinal tract of the rat. , 1998, Journal of pharmaceutical sciences.
[111] H Lennernäs,et al. Jejunal permeability and hepatic extraction of fluvastatin in humans , 1996, Clinical pharmacology and therapeutics.
[112] H. Lennernäs,et al. The Influence of Net Water Absorption on the Permeability of Antipyrine and Levodopa in the Human Jejunum , 1994, Pharmaceutical Research.
[113] M. Kasuga,et al. Real-time quantitative polymerase chain reaction for MDR1, MRP1, MRP2, and CYP3A-mRNA levels in Caco-2 cell lines, human duodenal enterocytes, normal colorectal tissues, and colorectal adenocarcinomas. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[114] U. Hofmann,et al. Increased Absorption of Digoxin from the Human Jejunum Due to Inhibition of Intestinal Transporter-Mediated Efflux , 2007, Clinical pharmacokinetics.
[115] N. Chalasani,et al. Inhibition of Human Intestinal Wall Metabolism by Macrolide Antibiotics: Effect of Clarithromycin on Cytochrome P450 3A4/5 Activity and Expression , 2005, Clinical pharmacology and therapeutics.
[116] D. Shen,et al. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. , 1997, Advanced drug delivery reviews.
[117] P. Artursson,et al. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[118] F. Lombardo,et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.
[119] C. Regårdh,et al. Pharmacokinetics of felodipine in patients with liver disease , 2004, European Journal of Clinical Pharmacology.
[120] Hans Lennernäs,et al. Jejunal Absorption and Metabolism of R/S-Verapamil in Humans , 1998, Pharmaceutical Research.
[121] M. Yamazaki,et al. Clinical Relevance of P-Glycoprotein in Drug Therapy , 2003, Drug metabolism reviews.
[122] D. Thakker,et al. Saturable Absorptive Transport of the Hydrophilic Organic Cation Ranitidine in Caco-2 Cells: Role of pH-Dependent Organic Cation Uptake System and P-Glycoprotein , 2006, Pharmaceutical Research.
[123] C. Porter,et al. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs , 2007, Nature Reviews Drug Discovery.
[124] M. Rowland,et al. Influence of Morphometric Factors on Quantitation of Paracellular Permeability of Intestinal Epithelia In Vitro , 1997, Pharmaceutical Research.
[125] U. Klotz,et al. Site-dependent small intestinal absorption of ranitidine , 2004, European Journal of Clinical Pharmacology.
[126] G. Amidon,et al. Human Intestinal Permeability of Piroxicam, Propranolol, Phenylalanine, and PEG 400 Determined by Jejunal Perfusion , 1997, Pharmaceutical Research.
[127] R. D. de Souza,et al. Colonic Health: Fermentation and Short Chain Fatty Acids , 2006, Journal of clinical gastroenterology.
[128] Hans Lennernäs,et al. Permeability and clearance views of drug absorption: A commentary , 1995, Journal of Pharmacokinetics and Biopharmaceutics.
[129] M. Zeidel,et al. The relationship between membrane fluidity and permeabilities to water, solutes, ammonia, and protons , 1995, The Journal of general physiology.
[130] L. Benet,et al. Comparison of Furosemide and Vinblastine Secretion from Cell Lines Overexpressing Multidrug Resistance Protein (P-Glycoprotein) and Multidrug Resistance-Associated Proteins (MRP1 and MRP2) , 2002, Pharmacology.
[131] H Lennernäs,et al. Jejunal permeability in humans in vivo and rats in situ: investigation of molecular size selectivity and solvent drag. , 1999, Acta physiologica Scandinavica.
[132] Anders Karlén,et al. Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. , 2003, Journal of molecular graphics & modelling.
[133] H. Lennernäs,et al. Regional intestinal absorption and biliary excretion of fluvastatin in the rat: possible involvement of mrp2. , 2004, Molecular pharmaceutics.
[134] D. Shen,et al. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism. , 1997, The Journal of pharmacology and experimental therapeutics.
[135] B. Goldin,et al. Intestinal microflora: metabolism of drugs and carcinogens. , 1990, Annals of medicine.
[136] Balázs Sarkadi,et al. The role of ABC transporters in drug resistance, metabolism and toxicity. , 2004, Current drug delivery.
[137] Patrick J. Sinko,et al. Characterization of the Regional Intestinal Kinetics of Drug Efflux in Rat and Human Intestine and in Caco-2 Cells , 1998, Pharmaceutical Research.
[138] J. Paulson,et al. Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate. , 1989, British journal of clinical pharmacology.
[139] A. Hedman. Inhibition by basic drugs of digoxin secretion into human bile , 1992, European Journal of Clinical Pharmacology.
[140] D. Meijer,et al. Stereoselective inhibition by the diastereomers quinidine and quinine of uptake of cardiac glycosides into isolated rat hepatocytes. , 1998, Journal of pharmaceutical sciences.
[141] Amin Rostami-Hodjegan,et al. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data , 2007, Nature Reviews Drug Discovery.
[142] J. Schellens,et al. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. , 2002, Cancer research.
[143] H. Glaeser,et al. P‐glycoprotein‐mediated intestinal and biliary digoxin transport in humans , 2003, Clinical pharmacology and therapeutics.
[144] David J Brayden,et al. Controlled release technologies for drug delivery. , 2003, Drug discovery today.
[145] R. Modigliani,et al. The method of intraluminal perfusion of the human small intestine. I. Principle and technique. , 1973, Digestion.
[146] Bertil Abrahamsson,et al. A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[147] P. Artursson,et al. Mechanism of Absorption Enhancement in Humans After Rectal Administration of Ampicillin in Suppositories Containing Sodium Caprate , 1997, Pharmaceutical Research.
[148] J. Schellens,et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[149] G R Wilkinson,et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. , 1999, Drug metabolism and disposition: the biological fate of chemicals.
[150] D A Smith,et al. Pharmacokinetics and metabolism in early drug discovery. , 1999, Current opinion in chemical biology.
[151] K. Schenck-Gustafsson,et al. Quinidine reduces biliary clearance of digoxin in man , 1987, European journal of clinical investigation.
[152] H. van de Waterbeemd. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. , 1998, European Journal of Pharmaceutical Sciences.
[153] Leslie Z Benet,et al. In Vivo Modulation of Intestinal CYP3A Metabolism by P-Glycoprotein: Studies Using the Rat Single-Pass Intestinal Perfusion Model , 2003, Journal of Pharmacology and Experimental Therapeutics.
[154] A. Amelsberg,et al. Carrier-mediated jejunal absorption of conjugated bile acids in the guinea pig. , 1996, Gastroenterology.
[155] M. D. de Jager,et al. Innovative Methods to Study Human Intestinal Drug Metabolism in Vitro: Precision-Cut Slices Compared with Ussing Chamber Preparations , 2006, Drug Metabolism and Disposition.
[156] A. Ungell,et al. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[157] L. Påhlman,et al. Variable expression of CYP and Pgp genes in the human small intestine , 2003, European journal of clinical investigation.
[158] M Rowland,et al. Species differences in size discrimination in the paracellular pathway reflected by oral bioavailability of poly(ethylene glycol) and D-peptides. , 1998, Journal of pharmaceutical sciences.
[159] P. Artursson,et al. Transport of celiprolol across human intestinal epithelial (Caco‐2) cells: mediation of secretion by multiple transporters including P‐glycoprotein , 1993, British journal of pharmacology.
[160] M. Hashida,et al. Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. , 2001, Biological & pharmaceutical bulletin.
[161] G. Amidon,et al. The Site-Specific Transport and Metabolism of Tacrolimus in Rat Small Intestine , 2003, Journal of Pharmacology and Experimental Therapeutics.
[162] H K Kroemer,et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. , 1999, The Journal of clinical investigation.
[163] H Lennernäs,et al. Human Jejunal Effective Permeability and Its Correlation with Preclinical Drug Absorption Models , 1997, The Journal of pharmacy and pharmacology.
[164] D. A. Johnson,et al. Determination of intrinsic membrane transport parameters from perfused intestine experiments: a boundary layer approach to estimating the aqueous and unbiased membrane permeabilities. , 1988, Journal of theoretical biology.
[165] M. Rowland,et al. Hepatic clearance of drugs. III. Additional experimental evidence supporting the “wellstirred” model, using metabolite (MEGX) generated from lidocaine under varying hepatic blood flow rates and linear conditions in the perfused rat liverin situ preparation , 1977, Journal of pharmacokinetics and biopharmaceutics.
[166] K. Danø. Active outward transport of daunomycin in resistant Ehrlich ascites tumor cells. , 1973, Biochimica et biophysica acta.
[167] Bengt Långström,et al. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development , 2003, European Journal of Clinical Pharmacology.
[168] T. Luckey. Introduction to intestinal microecology. , 1972, The American journal of clinical nutrition.
[169] H. Lennernäs,et al. The effect of L-leucine on the absorption of levodopa, studied by regional jejunal perfusion in man. , 1993, British journal of clinical pharmacology.
[170] Stephen S. Kim,et al. A perfusion bioreactor for intestinal tissue engineering. , 2007, The Journal of surgical research.
[171] L. Benet,et al. Contributions of saturable active secretion, passive transcellular, and paracellular diffusion to the overall transport of furosemide across adenocarcinoma (Caco-2) cells. , 2002, Journal of pharmaceutical sciences.
[172] A. Collett,et al. Comparison of P-glycoprotein-mediated drug-digoxin interactions in Caco-2 with human and rodent intestine: relevance to in vivo prediction. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[173] T. Walle,et al. Taxol transport by human intestinal epithelial Caco-2 cells. , 1998, Drug metabolism and disposition: the biological fate of chemicals.
[174] R. Riley,et al. The pivotal role of hepatocytes in drug discovery. , 2007, Chemico-biological interactions.
[175] G. Amidon,et al. Absorption potential: estimating the fraction absorbed for orally administered compounds. , 1985, Journal of pharmaceutical sciences.
[176] S. Riley,et al. Effects of a non-absorbable osmotic load on drug absorption in healthy volunteers. , 1992, British journal of clinical pharmacology.
[177] J. Schellens,et al. Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview. , 2002, The oncologist.
[178] M. Fromm,et al. Determination of in vivo absorption, metabolism, and transport of drugs by the human intestinal wall and liver with a novel perfusion technique , 2001, Clinical pharmacology and therapeutics.
[179] E. Näslund. Gastric Emptying: Comparison of Scintigraphic, Polyethylene Glycol Dilution, and Paracetamol Tracer Assessment Techniques , 2000, Scandinavian journal of gastroenterology.
[180] J. Hochman,et al. Evaluation of drug interactions with P-glycoprotein in drug discovery: in vitro assessment of the potential for drug-drug interactions with P-glycoprotein. , 2002, Current drug metabolism.
[181] P. Artursson,et al. A new principle for tight junction modulation based on occludin peptides. , 2003, Molecular pharmacology.
[182] Patrick J. Sinko,et al. Predicting Fraction Dose Absorbed in Humans Using a Macroscopic Mass Balance Approach , 1991, Pharmaceutical Research.
[183] H. Lennernäs,et al. Regional Intestinal Permeability in Rats of Compounds with Different Physicochemical Properties and Transport Mechanisms , 1997, The Journal of pharmacy and pharmacology.
[184] H. Lennernäs,et al. Regional transport and metabolism of ropivacaine and its CYP3A4 metabolite PPX in human intestine , 2003, The Journal of pharmacy and pharmacology.
[185] H. Lennernäs,et al. Multiple transport mechanisms involved in the intestinal absorption and first‐pass extraction of fexofenadine , 2003, Clinical pharmacology and therapeutics.
[186] H. Lennernäs,et al. Transport Characteristics of Fexofenadine in the Caco-2 Cell Model , 2004, Pharmaceutical Research.
[187] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[188] Jiunn H. Lin,et al. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. , 2003, Advanced drug delivery reviews.
[189] H. Lennernäs,et al. Rat Jejunal Permeability and Metabolism of μ-Selective Tetrapeptides in Gastrointestinal Fluids from Humans and Rats , 1997, Pharmaceutical Research.
[190] Y. Sugiyama,et al. HEPATIC TRANSPORT OF PKI166, AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR OF THE PYRROLO-PYRIMIDINE CLASS, AND ITS MAIN METABOLITE, ACU154 , 2004, Drug Metabolism and Disposition.
[191] K. Maeda,et al. SLCO1B1 (OATP1B1, an Uptake Transporter) and ABCG2 (BCRP, an Efflux Transporter) Variant Alleles and Pharmacokinetics of Pitavastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.
[192] A. Rosén,et al. Bioavailability and pharmacokinetics of cimetidine , 1979, European Journal of Clinical Pharmacology.
[193] H Lennernäs,et al. The Absence of Stereoselective P‐Glycoprotein‐mediated Transport of R/S‐Verapamil Across the Rat Jejunum , 1998, The Journal of pharmacy and pharmacology.
[194] H. Lennernäs,et al. The effect of ketoconazole on the jejunal permeability and CYP3A metabolism of (R/S)-verapamil in humans. , 1999, British journal of clinical pharmacology.
[195] C. Beglinger,et al. Relevance of p‐glycoprotein for the enteral absorption of cyclosporin A: in vitro‐in vivo correlation , 1996, British journal of pharmacology.
[196] H. Lennernäs,et al. CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. , 2001, Journal of pharmaceutical sciences.